Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
J Clin Microbiol ; 44(8): 2801-7, 2006 Aug.
Article in English | MEDLINE | ID: mdl-16891495

ABSTRACT

Herpes simplex virus type 1 (HSV-1) is transmitted by close contact, both sexual and nonsexual, and infections are acquired during childhood and adolescence. Herpes simplex virus type 2 (HSV-2), however, is thought to be transmitted mainly by sexual contact. Most HSV-2 infections are consequently expected to occur after the onset of sexual activity. Recent reports indicate an increasing prevalence of HSV-2 on the African continent, but most studies have been performed on adult cohorts. In the present study, we collected sera from Tanzanian children and young persons from 1 to 20 years old, with at least 100 individuals in each age group. Antibodies against HSV-1 and HSV-2 were detected by an in-house Western blot method which was shown to perform well in comparison with a commercial Western blot assay. Type-specific antibodies were also analyzed by two noncommercial enzyme-linked immunosorbent assay methods based upon the antigenicities of branched synthetic oligopeptides corresponding to epitopes in glycoprotein G of HSV-1 or HSV-2. The prevalence of HSV-1 antibodies increased gradually from 73% for the age group of 1 to 4 years to 92% for the age group of 17 to 20 years. The prevalence of HSV-2 antibodies was unexpectedly high, as 15% of the children were infected by the age of 8 years, with the incidence increasing gradually to 40% in the age group of 17 to 20 years. The reason for this unexpectedly high frequency is not clear but could suggest that nonsexual transmission of HSV-2 is more common than previously thought. There was no statistically significant association between seropositivities for HSV-2 and human immunodeficiency virus.


Subject(s)
Antibodies, Viral/blood , Herpes Simplex/epidemiology , Herpesvirus 1, Human/immunology , Herpesvirus 2, Human/immunology , Adolescent , Adult , Blotting, Western , Child , Child, Preschool , Enzyme-Linked Immunosorbent Assay , Female , HIV/immunology , Herpes Simplex/virology , Humans , Infant , Male , Seroepidemiologic Studies , Statistics as Topic , Tanzania/epidemiology , Urban Population/statistics & numerical data
2.
J Virol ; 80(13): 6247-58, 2006 Jul.
Article in English | MEDLINE | ID: mdl-16775312

ABSTRACT

We report the expression and characterization of the putative catalytic subunit (pORF30) and accessory protein (pORF18) of equine herpesvirus 1 DNA polymerase, which are encoded by open reading frames 30 and 18 and are homologous to herpes simplex virus type 1 UL30 and UL42, respectively. In vitro transcription-translation of open reading frames 30 and 18 generated proteins of 136 and 45 kDa, respectively. In vitro-expressed pORF30 possessed basal DNA polymerase activity that was stimulated by pORF18, as measured by DNA polymerase assays in vitro. Purified baculovirus-expressed pORF30 exhibited DNA polymerase activity similar to that of the in vitro-expressed protein, and baculovirus-expressed pORF18 could stimulate both nucleotide incorporation and long-chain DNA synthesis by pORF30 in a dose- and time-dependent manner. The salt optima for activity of both pORF30 and the holoenzyme were substantially different from those for other herpesvirus DNA polymerases. As demonstrated by yeast two-hybrid assays, pORF30 and pORF18 could physically interact, most likely with a 1:1 stoichiometry. Finally, by mutational analysis of the 1,220-residue pORF30, we demonstrated that the extreme C terminus of pORF30 is important for physical and functional interaction with the accessory protein, as reported for UL30 and other herpesvirus DNA polymerases. In addition, a C-proximal region of pORF30, corresponding to residues 1114 to 1172, is involved in binding to, and stimulation by, pORF18. Taken together, the results indicate that pORF30 and pORF18 are the equine herpesvirus 1 counterparts of herpes simplex virus type 1 UL30 and UL42 and share many, but not all, of their characteristics.


Subject(s)
DNA-Directed DNA Polymerase/genetics , Herpesvirus 1, Equid/genetics , Open Reading Frames/genetics , Viral Proteins/genetics , Amino Acid Substitution , Baculoviridae , Catalytic Domain/genetics , Cell-Free System , Cloning, Molecular , DNA, Viral/biosynthesis , DNA, Viral/chemistry , DNA-Directed DNA Polymerase/chemistry , Exodeoxyribonucleases/genetics , Gene Expression , Herpesvirus 1, Equid/enzymology , Holoenzymes/chemistry , Holoenzymes/genetics , Protein Binding/genetics , Protein Structure, Tertiary/genetics , Sequence Homology, Amino Acid , Two-Hybrid System Techniques , Viral Proteins/chemistry
3.
J Virol Methods ; 125(2): 137-43, 2005 May.
Article in English | MEDLINE | ID: mdl-15794983

ABSTRACT

Herpes simplex viruses types 1 and 2 (HSV-1 and HSV-2), which are common worldwide, are so similar that antibodies directed against one serotype may crossreact with antigens from the other one. Methods for specific detection of antibodies against HSV-1 or HSV-2 are based upon the antigenicities of glycoproteins G. However, due to the cost, the available commercial methods may not readily be used in developing countries. A different enzyme-linked immunosorbent assay (ELISA) method, based upon a synthetic oligopeptide corresponding to an immunogenic region in glycoprotein G of HSV-2, has been used recently and successfully for detection of HSV-2 antibodies. In the present study, the sequences of a newly identified immunogenic and type-specific region in glycoprotein G of HSV-1 was used to synthesize three different, branched oligopeptides. The performances of these peptides in an ELISA were investigated by testing Scandinavian and African sera which were characterized by commercial ELISA and Western blotting methods and divided into four groups either lacking HSV antibodies, containing antibodies against one or the other virus, or against both types. The peptide which corresponded in sequence to the immunodominant region was as specific and sensitive by an ELISA as were the commercial methods. The method is inexpensive and reliable.


Subject(s)
Antibodies, Viral , Enzyme-Linked Immunosorbent Assay/methods , Herpesvirus 1, Human/isolation & purification , Oligopeptides/immunology , Viral Envelope Proteins/analysis , Herpes Genitalis/diagnosis , Herpes Genitalis/immunology , Herpes Genitalis/virology , Herpesvirus 1, Human/immunology , Herpesvirus 2, Human/immunology , Humans , Immunodominant Epitopes/genetics , Immunodominant Epitopes/immunology , Sensitivity and Specificity , Viral Envelope Proteins/immunology
4.
J Virol ; 77(15): 8336-44, 2003 Aug.
Article in English | MEDLINE | ID: mdl-12857903

ABSTRACT

In common with other herpesviruses, the human cytomegalovirus (HCMV) DNA polymerase contains a catalytic subunit (Pol or UL54) and an accessory protein (UL44) that is thought to increase the processivity of the enzyme. The observation that antisense inhibition of UL44 synthesis in HCMV-infected cells strongly inhibits viral DNA replication, together with the structural similarity predicted for the herpesvirus processivity subunits, highlights the importance of the accessory protein for virus growth and raises the possibility that the UL54/UL44 interaction might be a valid target for antiviral drugs. To investigate this possibility, overlapping peptides spanning residues 1161 to 1242 of UL54 were synthesized and tested for inhibition of the interaction between purified UL54 and UL44 proteins. A peptide, LPRRLHLEPAFLPYSVKAHECC, corresponding to residues 1221 to 1242 at the very C terminus of UL54, disrupted both the physical interaction between the two proteins and specifically inhibited the stimulation of UL54 by UL44. A mutant peptide lacking the two carboxy-terminal cysteines was markedly less inhibitory, suggesting a role for these residues in the UL54/UL44 interaction. Circular dichroism spectroscopy indicated that the UL54 C-terminal peptide can adopt a partially alpha-helical structure. Taken together, these results indicate that the two subunits of HCMV DNA polymerase most likely interact in a way which is analogous to that of the two subunits of herpes simplex virus DNA polymerase, even though there is no sequence homology in the binding site, and suggest that the UL54 peptide, or derivatives thereof, could form the basis for developing a new class of anti-HCMV inhibitors that act by disrupting the UL54/UL44 interaction.


Subject(s)
Cytomegalovirus/enzymology , DNA-Binding Proteins/metabolism , DNA-Directed DNA Polymerase/chemistry , Nucleic Acid Synthesis Inhibitors , Peptides/pharmacology , Viral Proteins/metabolism , Amino Acid Sequence , Animals , Baculoviridae/genetics , Catalytic Domain , Cells, Cultured , Circular Dichroism , DNA-Binding Proteins/genetics , DNA-Directed DNA Polymerase/genetics , DNA-Directed DNA Polymerase/metabolism , Enzyme-Linked Immunosorbent Assay , Humans , Magnetic Resonance Spectroscopy , Molecular Sequence Data , Peptides/chemical synthesis , Peptides/chemistry , Protein Structure, Secondary , Spodoptera , Viral Proteins/genetics
5.
Rev Med Virol ; 12(4): 239-62, 2002.
Article in English | MEDLINE | ID: mdl-12125015

ABSTRACT

Most cellular and viral processes depend on the coordinated formation of protein-protein interactions. With a better understanding of the molecular biology and biochemistry of human viruses it has become possible to screen for and detect inhibitors with activity against specific viral functions and to develop new approaches for the treatment of viral infections. A novel strategy to inhibit viral replication is based on the disruption of viral protein-protein complexes by peptides that mimic either face of the interaction between subunits. Peptides and peptide mimetics capable of dissociating protein-protein interactions have such exquisite specificity that they hold great promise as the next generation of therapeutic agents. This review is focused on recent developments using peptides and small molecules to inhibit protein-protein interactions between cellular and/or viral proteins with comments on the practicalities of transforming chemical leads into derivatives with the characteristics desired of medicinal compounds.


Subject(s)
Antiviral Agents/pharmacology , Drug Design , Peptides/pharmacology , Proteins/metabolism , Viral Proteins/antagonists & inhibitors , Viral Proteins/metabolism , Antiviral Agents/chemistry , Humans , Peptides/chemistry , Protein Binding/drug effects , Virus Diseases/drug therapy , Viruses/drug effects , Viruses/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...